{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:48:24Z","timestamp":1778809704789,"version":"3.51.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-024-02729-4","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:28:05Z","timestamp":1736152085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-1958","authenticated-orcid":false,"given":"Johanne Juul","family":"Petersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Barkholt","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Faltermeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina Dam Bjerregaard","family":"Sillassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Jeronimo","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2729_CR1","doi-asserted-by":"publisher","first-page":"109083","DOI":"10.1016\/j.diabres.2021.109083","volume":"183","author":"GD Ogle","year":"2022","unstructured":"Ogle GD, James S, Dabelea D, Pihoker C, Svennson J, Maniam J, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: results from the International Diabetes Federation\u00a0Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183:109083.","journal-title":"Diabetes Res Clin Pract."},{"issue":"8","key":"2729_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2337\/diabetes.37.8.1113","volume":"37","author":"Geographic patterns of childhood insulin-dependent diabetes mellitus","year":"1988","unstructured":"Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes Epidemiology Research International Group. Diabetes. 1988;37(8):1113\u20139.","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"2729_CR3","doi-asserted-by":"publisher","first-page":"B75","DOI":"10.1007\/PL00002958","volume":"44","author":"C Levy-Marchal","year":"2001","unstructured":"Levy-Marchal C, Patterson CC, Green A, Europe EASG, Diabetes. Diabetes. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. European and Dibetes. Diabetologia. 2001;44(Suppl 3):B75-80.","journal-title":"Diabetologia."},{"issue":"3","key":"2729_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","volume":"39","author":"DM Maahs","year":"2010","unstructured":"Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481\u201397.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2729_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2021.11165","volume":"326","author":"JM Lawrence","year":"2021","unstructured":"Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001\u20132017. JAMA. 2021;326(8):717\u201327.","journal-title":"JAMA"},{"issue":"9513","key":"2729_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(06)68341-4","volume":"367","author":"D Daneman","year":"2006","unstructured":"Daneman D. Type 1 diabetes. Lancet. 2006;367(9513):847\u201358.","journal-title":"Lancet"},{"issue":"23","key":"2729_CR7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473\u20139.","journal-title":"JAMA"},{"key":"2729_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2431-13-124","volume":"13","author":"MA Penno","year":"2013","unstructured":"Penno MA, Couper JJ, Craig ME, Colman PG, Rawlinson WD, Cotterill AM, et al. Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatr. 2013;13:124.","journal-title":"BMC Pediatr"},{"issue":"8","key":"2729_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/pedi.13410","volume":"23","author":"REJ Besser","year":"2022","unstructured":"Besser REJ, Bell KJ, Couper JJ, Ziegler AG, Wherrett DK, Knip M, et al. ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1175\u201387.","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"2729_CR10","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1542\/peds.2013-2795","volume":"133","author":"D Dabelea","year":"2014","unstructured":"Dabelea D, Rewers A, Stafford JM, Standiford DA, Lawrence JM, Saydah S, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics. 2014;133(4):e938\u201345.","journal-title":"Pediatrics"},{"issue":"7","key":"2729_CR11","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2337\/dc20-0389","volume":"44","author":"ET Jensen","year":"2021","unstructured":"Jensen ET, Stafford JM, Saydah S, D\u2019Agostino RB, Dolan LM, Lawrence JM, et al. Increase in prevalence of diabetic ketoacidosis at diagnosis among youth with type 1 diabetes: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2021;44(7):1573\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"2729_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0044-102090","volume":"50","author":"J Grosse","year":"2018","unstructured":"Grosse J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with Human Development Index (HDI): an updated systematic review, meta-analysis, and meta-regression. Horm Metab Res. 2018;50(3):209\u201322.","journal-title":"Horm Metab Res"},{"issue":"8","key":"2729_CR13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/pedi.13444","volume":"23","author":"P Bjornstad","year":"2022","unstructured":"Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, et al. ISPAD clinical practice consensus guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1432\u201350.","journal-title":"Pediatr Diabetes"},{"key":"2729_CR14","unstructured":"Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva: World Health Organization; 2011."},{"issue":"Suppl 1","key":"2729_CR15","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.2337\/dc23-S014","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 14. Children and adolescents: standards of care in diabetes-2023. Diab Care. 2023;46(Suppl 1):S230\u201353.","journal-title":"Diab Care."},{"key":"2729_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yapd.2020.04.002","volume":"67","author":"C Ferber","year":"2020","unstructured":"Ferber C, Mao CS, Yee JK. Type 1 diabetes in youth and technology-based advances in management. Adv Pediatr. 2020;67:73\u201391.","journal-title":"Adv Pediatr"},{"key":"2729_CR17","unstructured":"(FDA) USFDA. Drug approvals and databases. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases."},{"issue":"3","key":"2729_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.spen.2006.01.001","volume":"12","author":"C Ryan","year":"2005","unstructured":"Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Seminars in Pediatric Neurology. 2005;12(3):163\u201377.","journal-title":"Seminars in Pediatric Neurology"},{"issue":"Suppl 1","key":"2729_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jped.2019.09.004","volume":"961 Suppl 1","author":"LE Calliari","year":"2020","unstructured":"Calliari LE, Almeida FJ, Noronha RM. Infections in children with diabetes. J Pediatr (Rio J). 2020;961 Suppl 1(Suppl 1):39\u201346.","journal-title":"J Pediatr (Rio J)."},{"issue":"2","key":"2729_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MAJ.0b013e3182449ff9","volume":"344","author":"AE Kitabchi","year":"2012","unstructured":"Kitabchi AE, Gosmanov AR. Safety of rapid-acting insulin analogs versus regular human insulin. Am J Med Sci. 2012;344(2):136\u201341.","journal-title":"Am J Med Sci"},{"key":"2729_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lfs.2019.01.011","volume":"219","author":"AK Sharma","year":"2019","unstructured":"Sharma AK, Taneja G, Kumar A, Sahu M, Sharma G, Kumar A, et al. Insulin analogs: glimpse on contemporary facts and future prospective. Life Sci. 2019;219:90\u20139.","journal-title":"Life Sci"},{"issue":"6","key":"2729_CR22","first-page":"CD012161","volume":"2016","author":"B Fullerton","year":"2016","unstructured":"Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;2016(6):CD012161.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"2729_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13300-019-00732-w","volume":"11","author":"A Nicolucci","year":"2020","unstructured":"Nicolucci A, Ceriello A, Di Bartolo P, Corcos A, Orsini FM. Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther. 2020;11(3):573\u201384.","journal-title":"Diabetes Ther"},{"issue":"3","key":"2729_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1590\/S1984-82502013000300011","volume":"49","author":"ACC Sanches","year":"2013","unstructured":"Sanches ACC, Correr CJ, Venson R, Gon\u00e7alves PR, Garcia MM, Piantavini MS, Pontarolo R. Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety. Braz J Pharm Sci. 2013;49(3):501\u20139.","journal-title":"Braz J Pharm Sci"},{"key":"2729_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13098-018-0397-3","volume":"11","author":"KFS Melo","year":"2019","unstructured":"Melo KFS, Bahia LR, Pasinato B, Porfirio GJM, Martimbianco AL, Riera R, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:2.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"2729_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s13300-018-0411-7","volume":"9","author":"K Norgaard","year":"2018","unstructured":"Norgaard K, Sukumar N, Rafnsson SB, Saravanan P. Efficacy and safety of rapid-acting insulin analogs in special populations with type 1 diabetes or gestational diabetes: systematic review and meta-analysis. Diabetes Ther. 2018;9(3):891\u2013917.","journal-title":"Diabetes Ther"},{"key":"2729_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5887","volume":"367","author":"R Rodriguez-Gutierrez","year":"2019","unstructured":"Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuniga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019;367: l5887.","journal-title":"BMJ"},{"issue":"25","key":"2729_CR28","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/sim.5403","volume":"31","author":"TR Fleming","year":"2012","unstructured":"Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973\u201384.","journal-title":"Stat Med"},{"key":"2729_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejim.2016.03.020","volume":"32","author":"S Garattini","year":"2016","unstructured":"Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. Eur J Intern Med. 2016;32:13\u201321.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"2729_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605\u201313.","journal-title":"Ann Intern Med"},{"issue":"9","key":"2729_CR31","first-page":"CD012143","volume":"9","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;9(9):CD012143.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"2729_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s13063-018-2978-8","volume":"19","author":"P Grey","year":"2018","unstructured":"Grey P, Grey A, Bolland MJ. Outcomes, interventions and funding in randomised research published in high-impact journals. Trials. 2018;19(1):592.","journal-title":"Trials"},{"issue":"1","key":"2729_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s13063-017-2364-y","volume":"18","author":"M Byrne","year":"2017","unstructured":"Byrne M, O\u2019Connell A, Egan AM, Dinneen SF, Hynes L, O\u2019Hara MC, et al. A core outcomes set for clinical trials of interventions for young adults with type 1 diabetes: an international, multi-perspective Delphi consensus study. Trials. 2017;18(1):602.","journal-title":"Trials"},{"issue":"8","key":"2729_CR34","doi-asserted-by":"publisher","first-page":"e004806","DOI":"10.1136\/bmjopen-2014-004806","volume":"4","author":"P Kahler","year":"2014","unstructured":"Kahler P, Grevstad B, Almdal T, Gluud C, Wetterslev J, Lund SS, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open. 2014;4(8):e004806.","journal-title":"BMJ Open"},{"issue":"14","key":"2729_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"C Diabetes","year":"1993","unstructured":"Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med."},{"key":"2729_CR36","unstructured":"Srinivasan B, Davies M, Lawrence I. Diabetes: glycaemic control in type 1. BMJ Clin Evid. 2008;2008:0607."},{"issue":"2","key":"2729_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.0954-6820.1988.tb16748.x","volume":"224","author":"P Reichard","year":"1988","unstructured":"Reichard P, Britz A, Cars I, Nilsson BY, Sobocinsky-Olsson B, Rosenqvist U. The Stockholm Diabetes Intervention Study (SDIS): 18 months\u2019 results. Acta Med Scand. 1988;224(2):115\u201322.","journal-title":"Acta Med Scand"},{"issue":"11","key":"2729_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/(SICI)1096-9136(199711)14:11<919::AID-DIA456>3.0.CO;2-A","volume":"14","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med. 1997;14(11):919\u201328.","journal-title":"Diabet Med"},{"key":"2729_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ\u202f: British Medical Journal. 2015;349: g7647.","journal-title":"BMJ : British Medical Journal"},{"issue":"1","key":"2729_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"2729_CR41","unstructured":"Guideline for good clinical practice E6(R2): Committee for Human Medicinal Products; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf."},{"issue":"6","key":"2729_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care."},{"issue":"5","key":"2729_CR43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"key":"2729_CR44","unstructured":"StataCorp. Stata statistical software: : College Station, TX: StataCorp LLC; 2019 Available from: http:\/\/www.stata.com."},{"key":"2729_CR45","unstructured":"TSA - trial sequential analysis: Copenhagen Trial Unit; Available from: http:\/\/www.ctu.dk\/tsa\/."},{"key":"2729_CR46","unstructured":"Thorlund KEJB, J; Imberger, G; Gluud, C. User manual for trial sequential analysis (TSA)2011. Available from: http:\/\/www.ctudk\/tsa\/files\/tsa_manualpdf."},{"key":"2729_CR47","unstructured":"The World Bank Group. World Bank Group country classifications by income level for FY24 (July 1, 2023- June 30, 2024) 2023 Available from: https:\/\/blogs.worldbank.org\/opendata\/new-world-bank-group-country-classifications-income-level-fy24."},{"key":"2729_CR48","doi-asserted-by":"publisher","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2(2):MR000033. https:\/\/doi.org\/10.1002\/14651858.MR000033.pub3.","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2729_CR49","unstructured":"Higgins JT, J; Chandler, J; Cumpston, M; Li, T; Page, M; Welch, V. Cochrane handbook for systematic reviews of interventions 2022. Available from: https:\/\/training.cochrane.org\/handbook\/current."},{"issue":"1","key":"2729_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials \u2013 a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.","journal-title":"BMC Med Res Methodol"},{"key":"2729_CR51","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch Ve. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) Cochrane: Cochrane; 2021. Available from: www.training.cochrane.org\/handbook."},{"issue":"11","key":"2729_CR52","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7414","key":"2729_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"20","key":"2729_CR54","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357.","journal-title":"Stat Med"},{"issue":"1","key":"2729_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","volume":"31","author":"DR Elbourne","year":"2002","unstructured":"Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140\u20139.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2729_CR56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2288-10-90","volume":"10","author":"F Keus","year":"2010","unstructured":"Keus F, Wetterslev J, Gluud C, van Laarhoven CJHM. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;10(1):90.","journal-title":"BMC Med Res Methodol"},{"key":"2729_CR57","doi-asserted-by":"publisher","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14(1):120.\u00a0https:\/\/doi.org\/10.1186\/1471-2288-14-120.","DOI":"10.1186\/1471-2288-14-120"},{"issue":"3","key":"2729_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"3","key":"2729_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/sim.4780060325","volume":"6","author":"DL Demets","year":"1987","unstructured":"Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6(3):341\u201350.","journal-title":"Stat Med"},{"issue":"1","key":"2729_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"2729_CR61","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2729_CR62","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"J Brok","year":"2009","unstructured":"Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive\u2013trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009;38(1):287\u201398.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2729_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","volume":"38","author":"K Thorlund","year":"2009","unstructured":"Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009;38(1):276\u201386.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2729_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-9-86","volume":"9","author":"J Wetterslev","year":"2009","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9(1):86.","journal-title":"BMC Med Res Methodol"},{"key":"2729_CR65","first-page":"57","volume":"2","author":"K Thorlund","year":"2010","unstructured":"Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clin Epidemiol. 2010;2:57\u201366.","journal-title":"Clin Epidemiol."},{"issue":"8","key":"2729_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011890","volume":"6","author":"G Imberger","year":"2016","unstructured":"Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open. 2016;6(8): e011890.","journal-title":"BMJ Open"},{"issue":"7650","key":"2729_CR67","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"4","key":"2729_CR68","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2729_CR69","first-page":"677","volume":"169","author":"HJ Sch\u00fcnemann","year":"2003","unstructured":"Sch\u00fcnemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677\u201380.","journal-title":"CMAJ"},{"key":"2729_CR70","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2288-10-90","volume":"10","author":"F Keus","year":"2010","unstructured":"Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;10:90.","journal-title":"BMC Med Res Methodol"},{"key":"2729_CR71","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. Copenhagen Trial Unit. TSA - trial sequential analysis. Available from: http:\/\/www.ctu.dk\/tsa\/."},{"key":"2729_CR72","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"2729_CR73","first-page":"677","volume":"169","author":"HJ Sch\u00fcnemann","year":"2003","unstructured":"Sch\u00fcnemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Can Med Assoc J. 2003;169:677\u201380.","journal-title":"Can Med Assoc J"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02729-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:06:00Z","timestamp":1736157960000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-024-02729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1186\/s13643-024-02729-4","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approve publication of the protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CDBS\u2019s husband is employed at Novo Nordisk, Kalundborg, Denmark, as \u201cfacility manager\u201d since September 1, 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}